Celldex Therapeutics Inc. (NASDAQ:CLDX) dropped 1.8% on Thursday . The company traded as low as $4.34 and last traded at $4.42, with a volume of 1,675,234 shares traded. The stock had previously closed at $4.50.

CLDX has been the topic of a number of research reports. Roth Capital restated a “buy” rating and set a $7.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, April 19th. Cowen and Company restated an “outperform” rating and set a $12.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, April 19th. Jefferies Group restated a “hold” rating and set a $4.00 price objective on shares of Celldex Therapeutics in a research report on Friday, May 6th. Finally, Wedbush restated a “neutral” rating and set a $3.00 price objective on shares of Celldex Therapeutics in a research report on Friday, May 6th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $14.22.

The stock’s 50-day moving average price is $4.57 and its 200 day moving average price is $4.93. The firm’s market cap is $438.38 million.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.02. The business earned $1.39 million during the quarter, compared to analysts’ expectations of $0.96 million. During the same quarter last year, the business posted ($0.33) EPS. The company’s quarterly revenue was down 36.4% on a year-over-year basis. On average, analysts predict that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Celldex Therapeutics stock. Rhumbline Advisers raised its position in Celldex Therapeutics Inc. (NASDAQ:CLDX) by 4.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 108,426 shares of the biopharmaceutical company’s stock after buying an additional 5,110 shares during the period. Rhumbline Advisers owned 0.11% of Celldex Therapeutics worth $1,700,000 as of its most recent SEC filing.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.